Abstract
Leptomeningeal dissemination of low-grade gliomas is an uncommon event. A 43-year old male presented with dizziness, gait ataxia, and diplopia. A nonenhancing lesion in the right cerebellar peduncle was identified, subtotally resected, and diagnosed as a grade II astrocytoma. After one year a nodular spread in the brain and leptomeninges was diagnosed, so the patient started chemotherapy with temozolomide and liposomal cytarabine. Complete remission was achieved after 12 months of treatment and the patient is still free from the disease after a follow-up of 24 months. We suggest that this combination may be a valuable treatment option.
References
Grier JT, Batchelor T (2006) Low-grade gliomas in adults. Oncologist 11:681–693
Arita N, Taneda M, Hayakawa T (1994) Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 126:84–92
Pollack IF, Hurtt M, Pang D, Albright AL (1994) Dissemination of low grade intracranial astrocytomas in children. Cancer 73:2869–2878
D’Haene N, Coen N, Neugroschl C, Balériaux D, Salmon I (2009) Leptomeningeal dissemination of low-grade intramedullary gliomas: about one case and review. Clin Neurol Neurosurg 111:390–394
Hukin J, Siffert J, Velasquez L, Zagzag D, Allen J (2002) Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro Oncol 4:253–260
Chamberlain MC (2005) Neoplastic meningitis. J Clin Oncol 23:3605–3613
Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S et al (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715–1721
Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133–3138
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM et al (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646–651
Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10(11):3728–3736
Murry DJ, Blaney SM (2000) Clinical pharmacology of encapsulated sustained-release cytarabine. Ann Pharmacother 34:1173–1178
Chamberlain MC, Kormanik P, Howell SB, Kim S (1995) Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52:912–917
Jaeckle KA, Batchelor T, O’Day SJ, Phuphanich S, New P, Lesser G et al (2002) An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 57:231–239
Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402
Lassaletta A, Perez-Olleros P, Scaglione C, Sirvent S, De Prada I, Perez-Martinez A et al (2007) Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. J Neurooncol 83(3):303–306
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Passarin, M.G., Moretto, G., Musso, A.M. et al. Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. J Neurooncol 97, 439–444 (2010). https://doi.org/10.1007/s11060-009-0040-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-009-0040-0